Skip to main content

Advertisement

Table 6 Characteristics and medical costs of patients in the non-persistent group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  Total BT-naïve
ADL IFX UST Sub total ADL IFX UST Subtotal
Number of patients 12 14 8 35 10 13 7 31
Average Age 46.1 47.3 50.5 47.8 47.9 48.5 51.1 49.1
%Female 8.3% 21.4% 12.5% 14.3% 10.0% 23.1% 14.3% 16.1%
Cost (pre) ¥595 ¥902 ¥808 ¥762 ¥367 ¥848 ¥621 ¥629
In 1000 JPY unit IP ¥0 ¥231 ¥32 ¥108 ¥0 ¥249 ¥36 ¥122
OP ¥332 ¥259 ¥448 ¥324 ¥81 ¥198 ¥232 ¥166
RX ¥263 ¥412 ¥328 ¥330 ¥286 ¥401 ¥353 ¥341
Cost increase ¥1504 ¥2507 ¥1828 ¥1937 ¥1620 ¥2608 ¥2254 ¥2126
In 1000 JPY unit IP ¥170 ¥933 ¥362 ¥511 ¥204 ¥1005 ¥414 ¥577
OP ¥932 ¥1749 ¥1638 ¥1395 ¥946 ¥1756 ¥2021 ¥1499
RX ¥402 - ¥175 - ¥172 ¥31 ¥470 - ¥153 - ¥181 ¥50
  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs